08.08.2022 - Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at the American Society of Clinical Oncology meetingPromising pre-clinical data on universal flu vaccine .
FLORHAM PARK, N.J., May 18, 2022 PDS Biotechnology Corporation , a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and. | May 18, 2022